South Korea-based Lunit, a leading provider of artificial intelligence (AI)-powered solutions for cancer diagnostics and therapeutics, has announced a strategic alliance with VIDI Group, the largest private radiology and radiotherapy network in France, to expand the deployment of its AI solution, Lunit INSIGHT MMG, across the network's extensive system of 400+ sites and 1,200 doctors.

This partnership represents a significant step in enhancing breast cancer screening efficiency and quality in France, with VIDI's network representing nearly a quarter of the French private radiology market.

The collaboration with VIDI builds on a track record of successful implementations across the network, with multiple VIDI members adopting Lunit INSIGHT MMG since 2021.

VIDI's decision to formalise its relationship with Lunit, following several successful real-life deployments, was announced at JFR 2024. Through this agreement, Lunit INSIGHT MMG will be listed as a recommended solution for all VIDI members, simplifying access and furthering VIDI's commitment to innovative healthcare solutions.

Through this partnership, Lunit aims to accelerate its footprint in the French market while also exploring broader collaboration opportunities with VIDI in education, communication, and product development, fostering further innovation in radiology.